Citadel Advisors
IMRX icon

Citadel Advisors’s Immuneering IMRX Stock Holding History

Citadel Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Sell
19,500
-32,200
-62% -$165K ﹤0.01% 12001
2025
Q4 		$340K Buy
+51,700
New +$332K ﹤0.01% 9870

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Citadel Advisors's IMRX Position: Q1 2026 in Review

Citadel Advisors increased its Immuneering (IMRX) stake by 394% in Q1 2026, buying an estimated $1.83M and bringing the position to 447,278 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #5743.

Citadel Advisors first reported a position in IMRX in Q3 2021 and has held it in 15 quarters since. The position peaked at $52.4M in Q3 2021. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Citadel Advisors held 447,278 shares of Immuneering worth $2.36M as of Q1 2026.
  • Citadel Advisors bought 356,819 Immuneering shares in Q1 2026, an estimated $1.83M.
  • Immuneering made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5743 holding.
  • Citadel Advisors first reported a position in Immuneering in Q3 2021 and has held it in 15 quarters since.
  • Citadel Advisors's Immuneering position peaked at $52.4M in Q3 2021.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.